Please use this identifier to cite or link to this item:
|Title:||Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.|
|Authors:||Schanstra, Joost P;Zürbig, Petra;Alkhalaf, Alaa;Argiles, Angel;Bakker, Stephan J L;Beige, Joachim;Bilo, Henk J G;Chatzikyrkou, Christos;Dakna, Mohammed;Dawson, Jesse;Delles, Christian;Haller, Hermann;Haubitz, Marion;Husi, Holger;Jankowski, Joachim;Jerums, George;Kleefstra, Nanne;Kuznetsova, Tatiana;Maahs, David M;Menne, Jan;Mullen, William;Ortiz, Alberto;Persson, Frederik;Rossing, Peter;Ruggenenti, Piero;Rychlik, Ivan;Serra, Andreas L;Siwy, Justyna;Snell-Bergeon, Janet;Spasovski, Goce;Staessen, Jan A;Vlahou, Antonia;Mischak, Harald;Vanholder, Raymond|
|Affiliation:||Institute of Cardiovascular and Metabolic Disease, French Institute of Health and Medical Research U1048, Toulouse, France; Paul Sabatier University (Toulouse III), Toulouse, France;|
mosaiques diagnostics GmbH, Hanover, Germany; firstname.lastname@example.org.
RD Néphrologie, Montpellier, France;
University Medical Center Groningen and University of Groningen, Groningen, The Netherlands;
KfH Renal Unit, Department Nephrology, Leipzig and Martin-Luther-University, Halle/Wittenberg, Germany;
University Medical Center Groningen and University of Groningen, Groningen, The Netherlands; Diabetes Centre, Isala Clinics, Zwolle, The Netherlands;
Department of Nephrology and Hypertension, University Hospital of Magdeburg, Magdeburg, Germany;
mosaiques diagnostics GmbH, Hanover, Germany;
Department of Nephrology and Hypertension, Medical School of Hanover, Hanover, Germany;
Department of Nephrology, Klinikum Fulda gAG, Fulda, Germany;
Institute for Molecular Cardiovascular Research, RWTH Aachen University Hospital, Aachen, Germany; Department of Internal Medicine IV, Charity Medical University of Berlin, Berlin, Germany;
Austin Health, University of Melbourne, Heidelberg, Australia;
Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven, Leuven, Belgium; Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium;
BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom;
School of Medicine, Jimenez Diaz Foundation Institute for Health Research, Autonomous University of Madrid, Madrid, Spain;
Steno Diabetes Center, Gentofte, Denmark;
Steno Diabetes Center, Gentofte, Denmark; Faculty of Health, University of Aarhus, Aarhus, Denmark; Faculty of Health, University of Copenhagen, Copenhagen, Denmark;
Mario Negri Institute of Pharmacology Research, Bergamo, Italy;
Second Department of Internal Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic;
Division of Nephrology, University Hospital, and Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland;
mosaiques diagnostics GmbH, Hanover, Germany; Department of Internal Medicine IV, Charity Medical University of Berlin, Berlin, Germany;
Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado;
University Department of Nephrology, Medical Faculty, University of Skopje, Skopje, Macedonia;
Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium;
Division of Biotechnology, Biomedical Research Foundation, Academy of Athens, Athens, Greece; and.
Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven, Leuven, Belgium;
Nephrology Section, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium.
|Citation:||Journal of the American Society of Nephrology : Jasn 2015; 26(8): 1999-2010|
|Abstract:||Progressive CKD is generally detected at a late stage by a sustained decline in eGFR and/or the presence of significant albuminuria. With the aim of early and improved risk stratification of patients with CKD, we studied urinary peptides in a large cross-sectional multicenter cohort of 1990 individuals, including 522 with follow-up data, using proteome analysis. We validated that a previously established multipeptide urinary biomarker classifier performed significantly better in detecting and predicting progression of CKD than the current clinical standard, urinary albumin. The classifier was also more sensitive for identifying patients with rapidly progressing CKD. Compared with the combination of baseline eGFR and albuminuria (area under the curve [AUC]=0.758), the addition of the multipeptide biomarker classifier significantly improved CKD risk prediction (AUC=0.831) as assessed by the net reclassification index (0.303±-0.065; P<0.001) and integrated discrimination improvement (0.058±0.014; P<0.001). Correlation of individual urinary peptides with CKD stage and progression showed that the peptides that associated with CKD, irrespective of CKD stage or CKD progression, were either fragments of the major circulating proteins, suggesting failure of the glomerular filtration barrier sieving properties, or different collagen fragments, suggesting accumulation of intrarenal extracellular matrix. Furthermore, protein fragments associated with progression of CKD originated mostly from proteins related to inflammation and tissue repair. Results of this study suggest that urinary proteome analysis might significantly improve the current state of the art of CKD detection and outcome prediction and that identification of the urinary peptides allows insight into various ongoing pathophysiologic processes in CKD.|
|Internal ID Number:||25589610|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.